

# Clinical Policy: Neonatal Sepsis Management

Reference Number: CP.MP.85

Date of Last Revision: 01/24

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

## Description

Through the increased incidence of intra-partum antibiotics, early-onset neonatal sepsis is occurring less frequently. However, it continues to be a common cause of neonatal morbidity and mortality.<sup>5</sup> The American Academy of Pediatrics defines Group B Streptococcus (GBS) early-onset disease as a blood or cerebrospinal fluid culture-proven infection occurring within the first seven days of life.<sup>8</sup>

Group B Streptococcus (GBS) remains the leading cause of early-onset neonatal sepsis and a major cause of late-onset sepsis.<sup>8</sup> More than half of GBS cases occur in infants of individuals with negative GBS cultures, emphasizing the need to remain vigilant for signs of sepsis in all newborns. In an effort to ensure timely treatment and to reduce morbidity and mortality, these infants require comprehensive assessment and treatment, as well as discharge planning.<sup>2,5</sup>

## Policy/Criteria

I. It is the policy of Health Plans affiliated with Centene Corporation<sup>®</sup> that the management of neonatal sepsis is medically necessary at the indicated level of care for the following circumstances:

A. Episode Day 1

1. Well-appearing infants who are on 48 hours of antibiotics pending blood culture results are appropriate for level II (rev code 172) nursery.
2. Symptomatic infants are appropriate for level III (rev code 173) nursery when meeting all of the following criteria:
  - a. Signs of neonatal sepsis (e.g.: hypotonia, lethargy, poor oral feeding, tachycardia, bradycardia, grunting, nasal flaring, cyanosis);
  - b. Temp  $\geq 100.4^{\circ}\text{F}$  or  $\leq 96.8^{\circ}\text{F}$  ( $\geq 38.0^{\circ}$  or  $\leq 36.0^{\circ}\text{C}$ );
  - c. On 48 hours of antibiotics pending blood culture results or treatment of positive blood cultures.

B. Episode Day 2 and Subsequent Days

1. Infants with negative cultures who are determined to require antibiotics beyond 48 hours may be appropriate for transitional care or level I nursery (rev code 171) once antibiotics are the only intervention necessitating continued stay and if outpatient antibiotics are inappropriate or unmanageable.
2. Symptomatic infants are appropriate for level III (rev code 173) nursery when meeting all of the following criteria:
  - a. Signs of neonatal sepsis (e.g.:hypotonia, lethargy, poor oral feeding, tachycardia, bradycardia, grunting, nasal flaring, cyanosis);
    - a. Temp  $\geq 100.4^{\circ}\text{F}$  or  $\leq 96.8^{\circ}\text{F}$  ( $\geq 38.0^{\circ}$  or  $\leq 36.0^{\circ}\text{C}$ );
3. On 48 hours of antibiotics pending blood culture results or treatment of positive blood cultures.

## CLINICAL POLICY

### Neonatal Sepsis Management

4. Asymptomatic infants on 48 hours of antibiotics pending blood culture results for  $\leq$  two days are appropriate for Level II (rev code 172) nursery.
5. Asymptomatic infants with a positive blood culture and no other indications are appropriate for transitional care.

Once the culture and sensitivity results are known and antibiotic therapy is established, a medically stable infant should be transitioned to a lower level of care for treatment completion if no other indications exist that require the current level of care.

It is difficult to administer intravenous antibiotics in the home with home health care due to the challenge of keeping very small catheters in place and patent. Transitional care nursery should be considered if antibiotics cannot safely be administered at home or at home with home health care.

- II. Discharge criteria, with or without home antibiotics, meets all of the following as applicable:
- A. Member/enrollee is clinically stable;
  - B. Home situation is assessed and deemed adequate;
  - C. Parent or caretaker is agreeable with the plan of care;
  - D. If going home with antibiotics, all of the following are met:
    1. Contractual agreement of care signed with a home infusion company experienced in neonatal IV (intravenous) therapy or short-term intramuscular therapy;
    2. Secure IV access is in place, if chosen;
    3. Contact information regarding the responsible physician (e.g., neonatologist, primary care pediatrician) and back-up health care facility (neonatal intensive care unit [NICU], community hospital) should be provided to the family and home care agency prior to discharge;
  - E. Provider follow up scheduled within 48 hours of discharge.

### Background

- I. *Identification and treatment of birthing individual during pregnancy and labor*<sup>6</sup>
- A. Birthing individuals with Group B streptococcus (GBS) isolated in the urine any time during the current pregnancy or who had a previous infant with invasive GBS disease should receive IV intrapartum antibiotic prophylaxis. Third trimester screening for GBS colonization is not needed in this population.
  - B. Birthing individuals with symptomatic or asymptomatic GBS urinary tract infection (UTI) detected during pregnancy should be treated according to current standards of care for UTI during pregnancy and should receive intrapartum antibiotic prophylaxis to prevent early-onset GBS disease.
  - C. All other pregnant individuals, including those with a scheduled cesarean delivery, should be screened at 36 0/7 through 37 6/7 weeks gestation for vaginal and rectal GBS colonization.
  - D. At the time of labor or rupture of membranes, intrapartum antibiotic prophylaxis should be given to all pregnant individuals whose vaginal-rectal cultures were positive for GBS colonization, including those undergoing cesarean delivery. If cesarean delivery is performed before onset of labor on a birthing individual with intact amniotic membranes, prophylaxis need not be given.

- E. When screening results are not available at the time of labor and delivery, intrapartum antibiotics should be given to birthing individuals who present in labor with a substantial risk of preterm birth, who have preterm pre-labor rupture of membranes (PPROM), rupture of membranes  $\geq 18$  hours at term, or who present with intrapartum temperature  $\geq 100.4^\circ\text{F}$  ( $\geq 38.0^\circ\text{C}$ ). If none of the above risks are present but there is a history of GBS colonization in a previous pregnancy, it is reasonable to offer intrapartum antibiotic prophylaxis and/or discuss it as an option in a shared decision-making process with the provider.
- F. If intraamniotic infection is suspected, broad-spectrum antibiotic therapy that provides coverage for polymicrobial infections as well as GBS should replace the antibiotic that provides coverage for GBS prophylaxis specifically.
- G. In the absence of GBS UTI that is symptomatic, or with GBS present at levels  $\leq 10^5$  colony forming units (CFU)/mL, antimicrobial agents should not be used before the intrapartum period to eradicate GBS genitoretal colonization because such treatment has not been shown to provide better outcomes to the birthing individual or neonate.
- H. Obstetric interventions, when necessary, should not be delayed solely to provide four hours of antibiotic administration before birth.

*II. Identification and Treatment of the newborn*

- A. Infants born at  $\geq 35$  weeks' gestation should be managed according to risk, as determined by categorical risk assessment, multivariate risk assessment (the Neonatal Early-Onset Sepsis Calculator <https://neonatalesepsiscalculator.kaiserpermanente.org/>), or clinical condition.<sup>8</sup>
- B. Preterm infants born at  $\leq 34$  weeks' are at highest risk for early-onset sepsis (EOS) in the following circumstances: Infants born preterm because of cervical insufficiency, preterm labor, PROM, intraamniotic infection, and/or acute and otherwise unexplained onset of nonreassuring fetal status are at the highest risk of EOS and GBS early-onset disease (EOD). A blood culture and initiation of empirical antibiotic treatment is recommended for infants with any of these risk factors.<sup>8</sup>
- C. Preterm infants born at  $\leq 34$  weeks are at lower risk for EOS when meeting all of the following: (1) maternal and/or fetal indications for preterm birth (such as maternal preeclampsia or other noninfectious medical illness, placental insufficiency, or fetal growth restriction), (2) birth by cesarean delivery, and (3) absence of labor, no attempts to induce labor, and no rupture of membranes (ROM) before delivery.
- D. For lower risk preterm infants, initial approaches include (1) no laboratory evaluation and no empirical antibiotic therapy or (2) blood culture and clinical monitoring. For infants who do not improve after initial stabilization and/or those who have severe systemic instability, the administration of empirical antibiotics may be reasonable but is not mandatory.<sup>8</sup>
- E. Physicians should use their best judgment to determine when cerebrospinal fluid analysis should be performed in the absence of bacteremia, as culture-confirmed meningitis in the absence of culture-confirmed bacteremia is approximately one to two cases per 100,000 live births.<sup>8</sup> However, the rate of meningitis is higher in preterm infants, and a lumbar puncture for culture and analysis of cerebrospinal fluid (CSF) should be considered in clinically ill infants when there is a high suspicion for GBS EOD, unless the procedure will compromise the neonate's clinical condition.<sup>8</sup>

**CLINICAL POLICY**  
**Neonatal Sepsis Management**

- F. Therapy for a term infant at risk of EOS should include antimicrobial agents active against GBS (including IV ampicillin and gentamicin), as well as other organisms that might cause neonatal sepsis, such as E. coli, et al.<sup>7</sup>
- G. Early-onset GBS infection is diagnosed by blood or CSF culture. Common laboratory tests such as the complete blood cell count and C-reactive protein do not perform well in predicting early-onset infection, particularly among well-appearing infants at lowest baseline risk of infection.<sup>8</sup> Procalcitonin has also been suggested as a biomarker for determining the risk of early-onset sepsis. However, it is not definitive in ruling in or ruling out an infection in neonates.

*III. General Considerations*

- A. Stable infants at 35 weeks gestational age or older who are treated for sepsis should be discharged the same day the antibiotics are discontinued.
- B. For ruling out sepsis due to perinatal risk factors, 36 to 48 hours of antibiotic administration is considered appropriate pending culture results and evaluation of lab data.
- C. When blood cultures are sterile, antibiotic therapy should be discontinued by 36 to 48 hours of incubation unless there is clear evidence of site-specific infection.<sup>7</sup>

Reviews, Revisions, and Approvals	Revision Date	Approval Date
Policy developed; Neonatologist reviewed	08/13	08/13
Policy reviewed by neonatologist and pediatrician.	05/19	
Edits to background information regarding identification and treatment of the mother, and identification and treatment of the newborn, per new ACOG and AAP guidelines.	07/19	07/19
Edits to background information regarding identification and treatment of the newborn per new AAP guidelines.	10/19	
Under section III. Discharge criteria, added E. Follow-up planned with provider within 48 hours of discharge. In background section I.G., changed $\geq 10^5$ CFU to $\leq 10^5$ CFU. References reviewed and updated.	06/20	07/20
Annual Review. Removed “or level 1 nursery (rev code 171),” from II.D: “Asymptomatic infants with a positive blood culture and no other indications are appropriate for transitional care or level 1 nursery (rev code 171).” Added sentence to note under criteria point II.D. to say, “It is difficult to administer intravenous antibiotics in the home with home health care due to the challenge of keeping very small catheters in place and patent.” Clarified III.D.3. that neonatologist, primary care pediatrician are examples of the responsible physician. References reviewed and updated. Replaced all instances of “member” with “member/enrollee”. Changed “review date” in the header to “date of last revision” and “date” in the revision log header to “revision date.” Sent for specialist review.	07/21	07/21
Annual review. Description updated. Background updated: Minor rewording for clarity in II.C; added verbiage about procalcitonin in II.G;	07/22	07/22

Reviews, Revisions, and Approvals	Revision Date	Approval Date
in III.B, changed 48 hours to 36 to 48 hours. References reviewed and updated. Reviewed by specialist.		
Annual review completed. Description and background updated. Minor rewording with no clinical significance. References reviewed and updated.	02/23	02/23
Annual review. Reworded description with no clinical significance. Reworded criteria under I.A.2. "when meeting all of the following criteria" with no impact to criteria. Expanded criteria under I.A.2.a. and I.B.2.a. "Signs of neonatal sepsis (e.g.: hypotonia, lethargy, poor oral feeding, tachycardia, bradycardia, grunting, nasal flaring, cyanosis). Reworded criteria under II.D.1., II.D.3. and II.E. with no impact to criteria. References reviewed and updated. Reviewed by external specialist.	01/24	01/24

**References**

1. Verani JR, McGee L, Schrag SJ; Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Prevention of perinatal group B streptococcal disease--revised guidelines from CDC, 2010. *MMWR Recomm Rep*. 2010;59(RR-10):1 to 36.
2. Polin RA. Management of Neonates with Suspected or Proven Early-Onset Bacterial Sepsis. *Pediatrics*. 2012;129(5):1006 to 1015. doi:10.1542/peds.2012-0541
3. Schuchat A, Zywicki SS, Dinsmoor MJ, et al. Risk factors and opportunities for prevention of early-onset neonatal sepsis: a multicenter case-control study. *Pediatrics*. 2000;105(1 Pt 1):21 to 26. doi:10.1542/peds.105.1.21.
4. Polin RA, Watterberg K, Benitz W, Eichenwald, E. The conundrum of early-onset sepsis. *Pediatrics*. 2014;133(6):1122 to 1123. doi:10.1542/peds.2014-0360
5. Edwards MS. Clinical features, evaluation and diagnosis of sepsis in term and late preterm infants. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated October 18, 2023. Accessed November 28, 2023.
6. Puopolo KM, Benitz WE, Zaoutis TE; Committee on fetus and newborn; committee on infectious diseases. Management of neonates born at  $\leq 34$  6/7 weeks' gestation with suspected or proven early-onset bacterial sepsis. *Pediatrics*. 2018;142(6):e20182896. doi:10.1542/peds.2018-2896
7. Puopolo KM, Benitz WE, Zaoutis TE; Committee on fetus and newborn; committee on infectious diseases. Management of neonates born at  $\geq 35$  0/7 weeks' gestation with suspected or proven early-onset bacterial sepsis. *Pediatrics*. 2018;142(6):e20182894. doi:10.1542/peds.2018-2894
8. Puopolo KM, Lynfield R, Cummings JJ; American Academy of Pediatrics, Committee on Fetus and Newborn, Committee on Infectious Diseases. Management of infants at risk for Group B streptococcal disease. *Pediatrics*. 2019;144(2):e20191881 doi:10.1542/peds.2019-1881.
9. Prevention of Group B Streptococcal Early-Onset Disease in Newborns: ACOG Committee Opinion, Number 797 [published correction appears in *Obstet Gynecol*. 2020

## CLINICAL POLICY

### Neonatal Sepsis Management

- Apr;135(4):978-979]. *Obstet Gynecol.* 2020;135(2):e51 to e72. doi:10.1097/AOG.0000000000003668.
10. Pammi M. Clinical features and diagnosis of bacterial sepsis in preterm infants < 34 weeks gestation. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated May 9, 2023. Accessed November 28, 2023.
  11. Puopolo, KM. Management of neonates at risk for early-onset group B streptococcal infection. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated May 9, 2023. Accessed November 28, 2023.
  12. Cantey JB, Prusakov P. A proposed framework for the clinical management of neonatal "culture-negative" sepsis. *J Pediatr.* 2022;244:203 to 211. doi:10.1016/j.jpeds.2022.01.006
  13. Paul SP, Khattak H, Kini PK, Heaton PA, Goel N. NICE guideline review: neonatal infection: antibiotics for prevention and treatment (NG195) [published online ahead of print, 2021 Nov 12]. *Arch Dis Child Educ Pract Ed.* 2021;edpract-2021-322349. doi:10.1136/archdischild-2021-322349
  14. Dhudasia MB, Flannery DD, Pfeifer MR, Puopolo KM. Updated Guidance: Prevention and management of perinatal Group B streptococcus infection. *Neoreviews.* 2021;22(3):e177 to e188. doi:10.1542/neo.22-3-e177
  15. Pammi M. Treatment and prevention of bacterial sepsis in preterm infants <34 weeks gestation. UpToDate. [www.uptodate.com](http://www.uptodate.com). Updated January 10, 2022. Accessed November 28, 2023.
  16. Choi Y, Han HS, Chong GO, et al. Updates on Group B *Streptococcus* Infection in the Field of Obstetrics and Gynecology. *Microorganisms.* 2022;10(12):2398. Published 2022 Dec 2. doi:10.3390/microorganisms10122398
  17. Ershad M, Mostafa A, Dela Cruz M, Vearrier D. Neonatal Sepsis. *Curr Emerg Hosp Med Rep.* 2019;7(3):83-90. doi:10.1007/s40138-019-00188-z
  18. Meenakshi Singh, Gray CP. Neonatal Sepsis. Nih.gov. Published July 15, 2019. <https://www.ncbi.nlm.nih.gov/books/NBK531478/>
  19. Briggs-Steinberg C, Roth P. Early-Onset Sepsis in Newborns. 2023;44(1):14-22. doi:https://doi.org/10.1542/pir.2020-001164
  20. Stoll BJ, Puopolo KM, Hansen NI, et al. Early-Onset Neonatal Sepsis 2015 to 2017, the Rise of *Escherichia coli*, and the Need for Novel Prevention Strategies [published correction appears in *JAMA Pediatr.* 2021 Feb 1;175(2):212]. *JAMA Pediatr.* 2020;174(7):e200593. doi:10.1001/jamapediatrics.2020.0593

### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. "Health Plan" means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members/enrollees. This clinical policy is not intended to recommend treatment for members/enrollees. Members/enrollees should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members/enrollees and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members/enrollees and their representatives agree to be bound by such terms and conditions by providing services to members/enrollees and/or submitting claims for payment for such services.

**Note: For Medicaid members/enrollees**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

**Note: For Medicare members/enrollees**, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed prior to applying the criteria set forth in this clinical policy. Refer to the CMS website at <http://www.cms.gov> for additional information.

## **CLINICAL POLICY**

### **Neonatal Sepsis Management**

©2016 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.